A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Paricalcitol
Latamoxef
The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Latamoxef.
Paricalcitol
Cephalothin Group
The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Cephalothin Group.
Paricalcitol
Hydrolyzed Cephalothin
The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Hydrolyzed Cephalothin.
Paricalcitol
Cefpodoxime
The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Aminophenazone.
Paricalcitol
Cefoxitin
The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Aminophenazone.
Paricalcitol
Cefonicid
The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Aminophenazone.
Paricalcitol
Cefprozil
The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Aminophenazone.
Paricalcitol
Cefapirin
The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Aminophenazone.
Paricalcitol
Colistimethate
The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Aminophenazone.
Paricalcitol
Cefditoren
The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Aminophenazone.
Paricalcitol
Ceforanide
The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Aminophenazone.
Paricalcitol
Canrenone
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Canrenone.
Paricalcitol
Canrenoic acid
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Canrenoic acid.
Paricalcitol
Cholestyramine
Cholestyramine can cause a decrease in the absorption of Aminophenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Paricalcitol
Colesevelam
Colesevelam can cause a decrease in the absorption of Aminophenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Paricalcitol
Omacetaxine mepesuccinate
The risk or severity of bleeding can be increased when Aminophenazone is combined with Omacetaxine mepesuccinate.
Paricalcitol
Enprostil
The therapeutic efficacy of Enprostil can be decreased when used in combination with Aminophenazone.
Paricalcitol
Latanoprostene bunod
The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Aminophenazone.
Paricalcitol
Fluprostenol
The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Aminophenazone.
Paricalcitol
Cloprostenol
The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Aminophenazone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3